EFFICACY AND SAFETY OF FIXED-DOSE COMBINATION OF ROSUVASTATIN AND IRBESARTAN IN PATIENTS WITH DYSLIPIDEMIA AND HYPERTENSION

Objectives: Hypertension and dyslipidemia are important major risk factors of cardiovascular disease. These are components of metabolic syndrome and are usually co-morbid and not so easy to achieve treatment goals with non-pharmaocological and pharmacological therapy.